Q-omics provides the consensus-scored SFTA3 profile across patient tissues and cancer cell-line models. SFTA3 expression is associated with patient survival in 19 of 34 cancer types, with the highest sampling consensus in LUSC. Among the 18 cancer types available for tumor–normal comparison, SFTA3 is differentially expressed in 5, with the highest sampling consensus in LUAD. Additionally, SFTA3 RNA expression shows 13,007 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight LUSC, LUAD, and LSCC as cancer lineages where SFTA3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for SFTA3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes SFTA3 survival associations across molecular data types. SFTA3 RNA expression shows survival associations in the most cancer types (19), followed by mutation status (2). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible SFTA3 RNA expression–survival associations across cancer types. High SFTA3 expression shows unfavorable associations in LUSC, KIRC, SCLC and SKCM, but favorable associations in LUAD and LGG. The LUSC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUSC as the clearest survival context for SFTA3 RNA expression.
This table summarizes SFTA3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for SFTA3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. SFTA3 shows lower tumor expression in LUAD, LUSC, KICH and KIRC and higher tumor expression in KIRP. The LUAD box plot shows higher SFTA3 RNA expression in normal versus tumor tissue (log2 FC = −2.289, t-test p < 0.001).
This table shows molecular features associated with SFTA3 in patient tissues and cancer cell lines. In patient samples, SFTA3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set. In cancer cell lines, SFTA3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BONE, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LUNG_NSCLC_LUAD.
